An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

Journal of Neuro-Oncology

Volumn 92, Issue 2, 2009, Pages 149-155

  Norden, Andrew D ^a,b,c   Drappatz, Jan ^a,b,c   Muzikansky, Alona ^a   David, Karly ^b   Gerard, Mary ^b   McNamara, M Brenna ^b   Phan, Phuong ^b   Ross, Ainsley ^b   Kesari, Santosh ^a,b,c   Wen, Patrick Y ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anti angiogenic therapy; Malignant glioma; Progression free survival

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; CYTOTOXIC AGENT; EDOTECARIN; GIMATECAN; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CARBAZOLES; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; SURVIVAL ANALYSIS;

EID: 61349199518     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9745-8     Document Type: Article

References (20)

1. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
2. Yung W, Albright R, Olson J, Fredericks R, Fink K, Prados M, Brada M, Spence A, Hohl R, Shapiro W, Glantz M, Greenberg H, Selker R, Vick N, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin V (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593. doi: 10.1054/bjoc.2000.1316
3. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771
4. Vredenburgh JJ, Desjardins A, Herndon JEII, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259. doi: 10.1158/1078-0432.CCR-06-2309
5. Cloughesy T, Prados M, Wen P, Mikkelson T, Abrey L, Schiff D, Yung WK, Paleologos N, Nicholas MK, Dorr A, Zheng M, Dimery I, Friedman H (2007) A phase II, randomized, non-comparative clinical trial of bevacizumab alone or in combination with CPT-11 prolongs 6-month PFS in recurrent, treatment-refractory glioblastoma. Society for Neuro-Oncology 12th Annual Meeting
6. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95. doi: 10.1016/ j.ccr.2006.11.021
7. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD (2008) Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-170. doi: 10.1215/ 15228517-2007-062
8. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
9. Lassman AB, Iwamoto FM, Gutin PH, Abrey LE (2008) Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM). J Clin Oncol 26:2028
10. Narayana A, Raza S, Golfinos JG, Johnson G, Knopp EA, Zagzag D, Fischer I, Medabalmi P, Eagan P, Gruber ML (2008) Bevacizumab therapy in recurrent high grade glioma: Impact on local control and survival. J Clin Oncol 26:13000
11. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787. doi: 10.1212/01.wnl.0000304121.57857.38
12. Zuniga RM, Torcuator R, Doyle T, Anderson J, Jain R, Orley J, Rosenblum M, Mikkelsen T (2008) Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan. J Clin Oncol 26:13013
13. Cloughesy TF, Prados MD, Mikkelsen T, Abrey LE, Schiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:2010b
14. Vredenburgh JJ, Desjardins A, Herndon JEII, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729. doi: 10.1200/JCO.2007.12.2440
15. Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Capelle F, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Desjardins A, Xuan KH, Chauffert B (2008) Bevacizumab/Irinotecan. An active treatment for recurrent high grade gliomas: Preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris) 164:588-594 doi: 10.1016/ j.neurol.2008.04.003
16. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258-1260. doi: 10.1212/ 01.wnl.0000208958.29600.87
17. Stark Vance V (2005) Bevacizumab (Avastin®) and CPT-11 (Camptosar®) in the Treatment of Relapsed Malignant Glioma. Neuro Oncol 7:369
18. Quant E, Norden AD, Drappatz J, Ciampa A, Doherty L, LaFrankie D, Kesari S, Wen PY (2008) Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen. J Clin Oncol 26:2008
19. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23:8136-8139. doi: 10.1200/JCO.2005.02.5635
20. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK Response criteria for glioma (2008) Nat Clin Pract Oncol 5:634-644